Multicenter Phase II Study of Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) to a split-dose CHP chemotherapy backbone will improve outcomes for elderly patients with a new diagnosis of diffuse large B-cell lymphoma.

Start Date01 Jun 2025

Sponsor / Collaborator

Medical College of Wisconsin

NCT06738368

/ Not yet recruitingPhase 2IIT

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) ± Rituximab + Recombinant Erwinia Asparaginase (JZP458; Rylaze®) for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Lymphoma/Leukemia

This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly diagnosed Philadelphia chromosome (Ph) negative B-acute lymphoblastic leukemia (ALL) or T-ALL. Chemotherapy drugs, such as etoposide, vincristine, cyclophosphamide and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. JZP458 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving DA-EPOCH with or without rituximab plus JZP458 may kill more cancer cells in patients with newly diagnosed Ph negative B-ALL or T-ALL.

Start Date01 Jun 2025

Sponsor / Collaborator

University of Washington

[+1]

NCT06124157

/ Not yet recruitingPhase 3IIT

A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia

This phase III trial compares the effect of the combination of blinatumomab with dasatinib and standard chemotherapy versus dasatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (PH+) or Philadelphia chromosome-like (Ph-Like) ABL-class B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib in combination with standard chemotherapy may work better in treating patients with PH+ or Ph-Like ABL-class B-ALL compared to dasatinib and chemotherapy alone.

Start Date29 May 2025

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Doxorubicin Hydrochloride

100 Translational Medicine associated with Doxorubicin Hydrochloride

100 Patents (Medical) associated with Doxorubicin Hydrochloride

92,032

Literatures (Medical) associated with Doxorubicin Hydrochloride

31 Dec 2025·DRUG DELIVERY

Incorporation of doxorubicin into plant-derived nanovesicles: process monitoring and activity assessment

Article

Author: Mucha, Piotr ; Jaikishan, Shishir ; Wielgomas, Bartosz ; Kalinowski, Leszek ; Heinz, Andrea ; Płoska, Agata ; Czyrski, Grzegorz S. ; Waleron, Krzysztof ; Wiedmer, Susanne K. ; Dziomba, Szymon ; Chen, Rui ; Targońska, Monika ; Jasiecki, Jacek ; Steć, Aleksandra

Extracellular vesicles (EVs) are an experimental class of drug carriers. Alternative sources of EVs are currently being explored to overcome limitations related to their manufacturing from mesenchymal stem cells. In this work, Citrus limon-derived EVs were tested as carriers for the widely used chemotherapeutic drug - doxorubicin (DOX). Capillary electrophoresis (CE) and nanoplasmonic sensing (NPS) were developed for the quality control of DOX-EV preparations. It was found that the CE method enables simultaneous detection of free and incorporated DOX and allows assessing the stability of the preparations and the drug leakage. NPS, on the other hand, demonstrated that DOX is accumulated in the interfacial region of the carrier. The activity of DOX-loaded EVs was tested on HeLa (cervical cancer cells) and HEK293T (human embryonic kidney cells) cell lines. It was found that DOX incorporation into plant-derived EVs virtually does not affect the drug's cytotoxicity to HeLa cells but significantly decreases DOX activity against HEK293T cell line.

01 Dec 2025·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Retraction Note: Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma

Article

Author: Guo, Yan ; Shang, Chao ; Zhang, Hui ; Song, Yongsheng

01 Jun 2025·PHYTOCHEMISTRY

Undescribed diterpenes from Euphorbia mauritanica L. as modulators of the breast cancer resistance: Mechanistic and in silico studies

Article

Author: Allam, Rasha M ; Essa, Ahmed F ; Elghonemy, Mai M ; Taher, Rehab F ; Elshamy, Abdelsamed I

As part of efforts to identify natural modulators of multi-drug-resistant breast cancer, Euphorbia mauritanica L. chloroform extract yielded four undescribed oxygenated diterpenes, including three nor-ent-abietanes, euphomauritanol C-E (1-3), and one polyacylated jatrophane, euphomauritanolide A (4), along with two knowns, helioscopinolide A (5) and enukokurin (6). The chemical structures and configurations of compounds were established by combination of HRMS, FTIR, and NMR spectroscopic tools along with experimental and calculated TDDFT-ECD. The cytotoxicity evaluation of isolated compounds against the MCF-7^ADR revealed 4 and 2 are the most potent with IC₅₀ values of 3.2 ± 0.58 and 4.67 ± 0.29 μM, respectively. Co-administration of compounds 4 and 2 with DOX improved its cytotoxic effect, with a combination index value of 0.41 for 4, indicating a synergistic effect. Mechanistically, 4 modulated DOX anticancer properties via potentiating DOX-induced Go/G1 cell cycle arrest rather than G2M arrest of DOX alone and shifting the cell death of DOX to be mainly apoptotic cell death. Furthermore, 4 alone and combined with DOX showed promising anti-migratory effects against MCF-7^ADR. In conclusion, 4 showed promising co-chemotherapeutic effects to the DOX against MCF-7^ADR, indicating that this compound possesses potential as an auspicious lead chemical to target breast cancer cells resistant to doxorubicin.

565

News (Medical) associated with Doxorubicin Hydrochloride

22 Feb 2025

·synapse.patsnap.com

Boosting anti-PD-1 PD-L1 therapy by targeting YTHDF1

The roles and mechanisms of the m6A reader protein YTHDF1 in tumor biologyHepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide. The development of HCC is influenced by both viral and non-viral factors. Non-alcoholic steatohepatitis (NASH) has emerged as a growing risk factor for HCC, as the prevalence of diabetes and metabolic syndrome increases. NASH is a progressive liver disease characterized by the accumulation of excessive triglycerides and is not caused by alcohol consumption. Although NASH is linked to the development of HCC, the molecular mechanisms underlying these diseases are not fully understood, which has hindered the development of effective treatments. Handicapping anti-PD1 therapyCurrently, there are no approved drugs or biological therapies specifically targeting NASH-related HCC (NASH-HCC). This deadly disease urgently requires new treatment methods. Immune checkpoint blockade (ICB) using monoclonal antibodies that target programmed cell death protein-1 (PD-1), programmed cell death-ligand 1 (PD-L1), or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has recently become a treatment option for HCC. However, NASH-HCC's poor response to ICB treatment is due to NASH-related immune changes in the liver. Therefore, identifying potential therapeutic targets is critical to overcoming resistance to ICB treatment in NASH-HCC. YTHDF1, a m6A reader, is upregulated in human NASH-HCC tumors compared to peri-tumor tissues.N6-methyladenosine (m6A) is the most prevalent chemical modification in eukaryotic mRNA and is known to play a crucial role in post-transcriptional regulation. m6A modification regulates RNA fate by controlling RNA stability, processing, transport, localization, translation, and RNA-protein interactions. YTH domain-containing family protein 1 (YTHDF1) is a translation-promoting m6A reader that targets mRNAs in the cytoplasm and contributes to tumor progression by regulating cell proliferation, DNA damage, and immunity. YTHDF1 deficiency in mice enhances antigen-specific CD8+ T cell-mediated anti-tumor responses in colorectal and gastric cancers, making it a potential therapeutic target for cancer immunotherapy. However, the role of YTHDF1 in the pathogenesis of HCC, particularly NASH-HCC, and its regulation of the tumor immune microenvironment are currently not well understood. A recent study published in Journal of Hepatology provides valuable insights into YTHDF1’s role in the progression of NASH-HCC. It is the first to demonstrate that tumor-intrinsic YTHDF1 is linked to the accumulation of myeloid-derived suppressor cells (MDSCs) in the NASH-HCC microenvironment. In transgenic mice with liver-specific YTHDF1 overexpression, YTHDF1 induces MDSC infiltration and accelerates spontaneous NASH-HCC. Ythdf1 recruits MDSCs via IL-6 in NASH-HCC.The signaling cascade of YTHDF1 activates the EZH2-IL-6 signaling pathway to recruit MDSCs, resulting in T cell dysfunction and promoting tumor growth. Conversely, targeting YTHDF1 with lipid nanoparticle (LNP)-siRNA can significantly enhance the anti-PD-1 blockade effect in NASH-HCC mouse models, suggesting that YTHDF1 is a new target for enhancing the efficacy of immune checkpoint blockade therapy in NASH-HCC. This is not the first time YTHDF1's role in cancer pathology has been elucidated. Last year, a study reported that YTHDF1 promotes breast cancer cell growth in both in vitro and in vivo environments and plays a crucial role in DNA damage repair and chemoresistance. And it seems that YTHDF1 modulates E2F8 mRNA stability and DNA damage repair in a METTL14-dependent manner. METTL14 is involved in DNA replication, DNA damage repair and chemoresistance.On the other hand, YTHDF1 knockdown has been shown to sensitize breast cancer cells to Adriamycin and Cisplatin, as well as Olaparib, a PARP inhibitor. During the experiments, researchers observed that the knockdown of YTHDF1 in MDA-MB-231 cells resulted in a reduction of S-phase fraction and an increased G1-phase fraction. The YTHDF1 knockdown also downregulated CDK2 and Cyclin E2, while upregulating P21, a CDK inhibitor involved in S-phase. YTHDF1’s roles in other types of cancer have been revealed as well. A study published earlier this year has suggested that YTHDF1 may play an important role in shaping the immune microenvironment of colorectal cancer (CRC). In their study, the team of researchers revealed that removing YTHDF1 from mouse CRC cells (both microsatellite stable (MSS) and microsatellite instable-high (MSI-H) varieties) results in an accumulation of myeloid-derived suppressor cells (MDSCs). This accumulation subsequently inhibits the infiltration of T cells in both mouse CRC models and humanized mouse models, demonstrating a deep interconnectedness. The investigation led to the identification of p65/Rela as a target of YTHDF1. The researchers observed that YTHDF1 encouraged the production of p65 protein, which in turn escalated the regulation of CXCL1. This process amplified the migration of MDSCs through the CXCL1-CXCR2 pathway, resulting in an increased number of MDSCs. These MDSCs then countered the function of CD8+ T cells within the tumor immune microenvironment (TIME). This intricate research, along with the others discussed here, suggest that the strategic targeting of YTHDF1, potentially using techniques such as CRISPR or VNPs-siYTHDF1, could enhance the efficacy of anti-PD1 therapy in a variety of cancers. References: 1.Wang L. et al., Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts anti-tumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis 2, Journal of Hepatology, Available online 17 July 2023. 2.Sun, Y., Dong, D., Xia, Y. et al. YTHDF1 promotes breast cancer cell growth, DNA damage repair and chemoresistance. Cell Death Dis 13, 230 (2022). 3.Bao Y, Zhai J, Chen H, et al, Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer, Gut 2023;72:1497-1509. The content above comes from the network. if any infringement, please contact us to modify.

11 Feb 2025

·www.globenewswire.com

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital MarketTORONTO and PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") today announced that it has entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD (the “Investor”), an investment fund managed by Yorkville Advisors Global, LP. Pursuant to the SEPA, the Company has the option, at its sole discretion, to sell up to US$15,000,000 of the Company’s common shares (the “Shares”) to the Investor at any time during the 36-months following the date of the SEPA. The Investor’s obligation to purchase Shares is subject to a number of conditions, including that the Company file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the Shares issuable thereunder, and that the registration statement is declared effective by the SEC. The total number of Shares issuable under the terms of the SEPA is limited to a number equivalent to 19.99% of the outstanding Shares as of the date of the SEPA unless certain pricing conditions are met, which could have the effect of limiting the total proceeds made available to the Company under the SEPA. The issuance of Shares under the SEPA is subject to further limitations, including that the Shares beneficially owned by the Investor and its affiliates at any one time will not exceed 4.99% of the then-outstanding Shares. Shares issued and sold to the Investor under the SEPA will be priced at 97% of the Market Price (as defined in the SEPA) of the Shares during a specified three-day pricing period. The Company reserves the right to set a minimum acceptable price for the Share issuances. For further information on the SEPA, including important terms and conditions, please see the Company’s filings with the SEC, including the Company’s Current Reports on Form 8-K filed with the SEC from time to time. TSXV Delisting The Company also today announced that the Company's board of directors has approved the voluntary delisting (the "Delisting") of the Shares from the TSX Venture Exchange (the "TSXV"). The Company has submitted an application to the TSXV to complete such Delisting in due course. Following review of the Company's application, the Delisting will be subject to the approval of the TSXV and the satisfaction of all necessary conditions. The Shares will continue to be listed on The Nasdaq Capital Market ("Nasdaq") under the symbol "MDCX" and shareholders will be able to continue to trade their Shares through Nasdaq. Trading on Nasdaq represents the large majority of the Company's trading volume. Given the low trading volume on the TSXV, the Company has determined, after due consideration, that maintaining the TSXV listing does not form part of the Company's go-forward capital markets strategy. The Company is not required to seek shareholder approval for the Delisting since an alternative market for the Shares exists on Nasdaq. Medicus will remain a "reporting issuer" in Canada and will continue to provide disclosure on SEDAR+ as required by applicable Canadian securities laws. Additional information regarding the Delisting application will be disseminated in due course. Many brokers in Canada, including discount and online brokers, can buy and sell securities listed on Nasdaq. Shareholders holding Shares in Canadian brokerage accounts may contact their brokers to confirm how to trade their Shares on Nasdaq. For further information contact: Carolyn Bonner, President(610) 636-0184cbonner@medicuspharma.com Jeremy FefferLifeSci Advisors(212) 915-2568jfeffer@lifesciadvisors.com About Medicus Pharma Ltd: Medicus Pharma Ltd. (Nasdaq: MDCX, TSXV: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company submitted a Phase 2 IND clinical protocol to the FDA in January 2024 for a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) that is expected to randomize up to 60 patients. The study is designed to evaluate the efficacy of two dose of two dose levels (100 and 200 ug) of D-MNA compared to placebo (P-MNA) in subjects with nodular BCC. Patient recruitment is currently underway in nine sites across the United States. Cautionary Notice on Forward-Looking Statements Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the amount of Shares the Company may issue pursuant to the SEPA, if any, the terms and conditions of the SEPA, including the requirement to have an effective registration statement with the SEC, the Company’s intention to delist the Shares from the TSXV, including approval from the TSXV and the timing thereof and the expectation that a market will continue to exist for the Shares on Nasdaq. Forward-looking statements are often but not always identified by the use of such terms as “may”, “might”, “will”, “will likely result”, “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s public filings on SEDAR+ and on EDGAR, which may impact, among other things, the trading price and liquidity of the Shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned that the foregoing list is not exhaustive and readers are encouraged to review the Company’s long form prospectus accessible on the Company’s profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Phase 1Phase 2Clinical Result

06 Feb 2025

·www.businesswire.com

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin and prednisone (R-CHP) compared to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) alone, for the treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Zilovertamab vedotin is Merck’s investigational antibody-drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1). Global recruitment of the waveLINE-010 trial has begun, with patients now enrolling. “ Following the encouraging results observed in the Phase 2 waveLINE-007 trial, we look forward to evaluating the potential clinical benefits of a combination regimen with zilovertamab vedotin in patients with diffuse large B-cell lymphoma compared to the current standard treatment,” said Dr. Gregory Lubiniecki, vice president, oncology clinical research, Merck Research Laboratories. “ ADCs have shown promise as an important modality in the treatment of different cancer types, and the initiation of this Phase 3 waveLINE clinical trial demonstrates our commitment to researching zilovertamab vedotin to help address unmet needs for patients with this aggressive and most common form of non-Hodgkin lymphoma.” WaveLINE-010 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT06717347 ), which is enrolling an estimated 1,046 patients globally. The primary endpoint is progression-free survival (PFS), and secondary endpoints include complete response (CR) rate at the end of the treatment, overall survival, event-free survival, duration of CR and safety. Zilovertamab vedotin is currently being evaluated in the Phase 2/3 waveLINE-003 dose confirmation and expansion trial ( NCT05139017 ) for the treatment of relapsed or refractory DLBCL and in the Phase 2 waveLINE-007 trial ( NCT05406401 ) in combination with R-CHP in patients with previously untreated DLBCL. Merck recently presented data from this trial for the first time at the 66 th American Society of Hematology Annual Meeting and Exposition in December 2024. About diffuse large B-cell lymphoma Lymphoma is cancer beginning in the lymphatic system – the network of organs, vessels and tissues that protects the body from infection. There are many subtypes of lymphoma, which is often categorized into two main types – Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma, the most common form of NHL, is derived from white blood cells that grow rapidly and uncontrollably, enlarging the lymph nodes and often migrating to other parts of the body. DLBCL accounts for approximately 25-30% of all NHLs worldwide. In the U.S., it is estimated that approximately 25,000 patients are diagnosed with DLBCL each year. The five-year relative survival rate for DLBCL is 60-70%. About zilovertamab vedotin (MK-2140) Zilovertamab vedotin is an investigational ADC that targets ROR1. ROR1 is a transmembrane protein that is overexpressed in multiple hematologic malignancies. Merck is committed to research with zilovertamab vedotin across B-cell malignancies and is establishing a robust program of clinical trials under the name waveLINE. The waveLINE program includes a Phase 2/3 study in patients with relapsed or refractory DLBCL (waveLINE-003, NCT05139017 ) and a Phase 2 study in patients with previously untreated DLBCL (waveLINE-007, NCT05406401 ). About Merck in hematology Merck is committed to advancing innovation and care for people with hematologic neoplasms and malignancies. Building on its leadership in oncology, the company has a broad clinical development program that evaluates novel mechanisms of action to address longstanding unmet needs for patients with hematologic disorders. Among Merck’s research efforts are studies evaluating multiple investigational medicines as monotherapy or in combination with other therapies across a range of hematologic neoplasms and malignancies. Merck’s focus on cancer Every day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncology . About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter) , Facebook , Instagram , YouTube and LinkedIn . Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( www.sec.gov ).

Phase 2Phase 3ASH

100 Deals associated with Doxorubicin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01275	Doxorubicin Hydrochloride	L01DB01	DB00997

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
AIDS-related Kaposi Sarcoma	JP	Baxter Holdings Ltd. (Japan)	04 Jan 2007
Kaposi Sarcoma	JP	Mochida Pharmaceutical Co., Ltd.	04 Jan 2007
Bone Cancer	JP	Sandoz AG	14 Feb 2005
Bone Tissue Neoplasms	JP	Sandoz AG	14 Feb 2005
Childhood Malignant Solid Neoplasm	JP	Sandoz AG	14 Feb 2005
Endometrial Carcinoma	JP	Sandoz AG	14 Feb 2005
Ewing Sarcoma	JP	Sandoz AG	14 Feb 2005
Hepatoblastoma	JP	Sandoz AG	14 Feb 2005
Multiple Myeloma	JP	Sandoz AG	14 Feb 2005
Retinoblastoma	JP	Sandoz AG	14 Feb 2005
Rhabdomyosarcoma	JP	Sandoz AG	14 Feb 2005
Soft Tissue Neoplasms	JP	Sandoz AG	14 Feb 2005
Transitional Cell Carcinoma	JP	Sandoz AG	03 Jan 2004
Lung Cancer	CN	Pfizer Pharmaceutical (Wuxi) Co. Ltd.	01 Jan 2001
Ovarian Cancer	US	Pfizer Inc.	23 Dec 1987
Stomach Cancer	US	Pfizer Inc.	23 Dec 1987
Bladder Cancer	JP	Sandoz AG	22 May 1979
Acute Lymphoblastic Leukemia	US	Pfizer Inc.	07 Aug 1974
Acute Myeloid Leukemia	US	Pfizer Inc.	07 Aug 1974
Breast Cancer	US	Pfizer Inc.	07 Aug 1974

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	NDA/BLA	CN	NATCO Pharma Ltd.	30 Jan 2022
Neoplasms	NDA/BLA	CN	Dr. Reddy's Laboratories Ltd.	30 Jan 2022
Early Stage Breast Carcinoma	Phase 3	DE	Teva Pharmaceuticals USA, Inc.	01 Jul 2014
Recurrent ovarian cancer	Phase 3	CN	Xian-Janssen Pharmaceutical Ltd.	01 Jun 2013
Locally advanced breast cancer	Phase 3	-	Sanofi SA	01 Sep 2002
Locally advanced breast cancer	Phase 3	-	Amgen, Inc.	01 Sep 2002
Locally advanced breast cancer	Phase 3	-	Roche Pharma AG	01 Sep 2002
Ovarian Epithelial Carcinoma	Phase 3	-	SEQUUS Pharmaceuticals, Inc.	01 May 1997
Ovarian Epithelial Carcinoma	Phase 3	-	Johnson & Johnson Pharmaceutical Research & Development LLC	01 May 1997
Classical Hodgkin's Lymphoma	Phase 2	US	Merck Sharp & Dohme Corp.	14 Dec 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03742258 (CTgov)	Phase 1	High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements \| T-cell/histiocyte rich large B-cell lymphoma	12	Spleen Tyrosine Kinase Inhibitor+Cyclophosphamide+Prednisone+doxorubicin hydrochloride+Rituximab+Vincristine Sulfate+TAK-659 (TAK-659 60mg + R-CHOP)	myoskrgerz(rmfyvwtkin) = unuxebwxib bmjymrtget (dybwwzixoz, qtrtvipmlq - lzdcsmhurx) View more	-	29 Jan 2025
				Doxorubicin Hydrochloride+Spleen Tyrosine Kinase Inhibitor+Cyclophosphamide+Prednisone+Rituximab+Vincristine Sulfate+TAK-659 (TAK-659 80mg + R-CHOP)	myoskrgerz(rmfyvwtkin) = pzzjlpdfzb bmjymrtget (dybwwzixoz, iqwxixyhtu - uixzpzutev) View more
NCT03331341 (4429, CTgov)	Phase 1/2	Classical Hodgkin's Lymphoma	50	Laboratory Biomarker Analysis+Dacarbazine+Doxorubicin Hydrochloride+pembrolizumab+Vinblastine	gixicnlqqz(uqszxdyhbg) = isfoeciwer mkhjvwdebi (knivdkpvcf, mxmnigxvxs - mzkksvdfhk) View more	-	09 Jan 2025
NCT01897441 (CTgov)	Not Applicable	Metastatic breast cancer \| Breast Cancer 3 \| Advanced breast cancer	31	Cytology Specimen Collection Procedure+Trastuzumab+cyclophosphamide+Doxorubicin Hydrochloride+Paclitaxel (Stratum A: HER2-positive)	wrhemwgati(tuicxfixtg) = khnxlkjjtg pdoqdqcejz (tfoyhrhspc, snzxkwukdf - zubnzlmpqk) View more	-	24 Dec 2024
				Cytology Specimen Collection Procedure+cyclophosphamide+Doxorubicin Hydrochloride+Paclitaxel (Stratum B: HER2-negative)	wrhemwgati(tuicxfixtg) = atejflemss pdoqdqcejz (tfoyhrhspc, cghmirpuzh - pvjftmpqkt) View more
NCT00170573 (CTgov)	Phase 2	Platinum-Sensitive Primary Peritoneal Carcinoma \| Recurrent ovarian cancer	77	Caelyx	wkzptfyxhm(tqiwuuvaxa) = ddvxsdvewx plzrvkzksm (wjafzhwlhs, dlvbkpfywt - vznxfepebv) View more	-	16 Dec 2024
NCT04996004 (TTI-621-03, CTgov)	Phase 2	Leiomyosarcoma	76	Doxorubicin+Ontorpacept (Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin)	nrmcubwpbx(xorbqhcmql) = ckpvjmlooi qhpidbcitz (rqzbezkhtx, chijckqekp - ycdupfbauz) View more	-	11 Dec 2024
				Doxorubicin+Ontorpacept (Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin)	nrmcubwpbx(xorbqhcmql) = pzhmkylcxe qhpidbcitz (rqzbezkhtx, zpuefqvlsl - xgfejrjrdy) View more
NCT03274492 (POLARIX, ASH2024) Manual	Phase 3	Diffuse Large B-Cell Lymphoma	879	Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP)Prednisone (Pola-R-CHP)	qeylnnqxnc(iurffxfmal) = ecihfvbmqw cxjkxrawrq (ogjmsqkkdz, 65.46 - 77.05) View more	Positive	08 Dec 2024
				Rituximab + Cyclophosphamide + Doxorubicin + Vincristine +Prednisone (R-CHOP)	qeylnnqxnc(iurffxfmal) = mtcuyinruz cxjkxrawrq (ogjmsqkkdz, 59.45 - 71.45) View more
ASH2024	Not Applicable	Hodgkin's Lymphoma	-	Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP)	nxwhjdsggq(dsyyqzyirs) = Primary G-CSF support documented in 98% of patients ciqweaxrfn (pslozlnwui ) View more	-	08 Dec 2024
ASH2024	Not Applicable	Non-Hodgkin Lymphoma	-	Levofloxacin 500 mg	wpycnrybkb(sojlbqfsuc) = loaklgdpaw pitqwsfjpb (ikrmeqgugj ) View more	-	07 Dec 2024
				Placebo	sedbjfqujj(zyxweflgrw) = uxnkbuwmcn uciuzadatm (wownbxwvyf ) View more
NCT02641847 (BCTOP-T-A01, Literature) Manual	Phase 3	Triple Negative Breast Cancer	498	docetaxel+doxorubicin or epirubicin+cyclophosphamide+gemcitabine+cisplatin (High risk group A)	urwgnhreoe(rqliwczhvt) = jfpbibeqsd zngtnqynlc (pwkgotsjyv ) View more	Positive	23 Oct 2024
				docetaxel+doxorubicin or epirubicin+cyclophosphamide (High risk group B)	urwgnhreoe(rqliwczhvt) = ayeoswbhkc zngtnqynlc (pwkgotsjyv ) View more
NCT03907488 (S1826, Pubmed) Manual	Phase 3	Classical Hodgkin's Lymphoma	994	Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (BV+AVD)	lssvswztwo(wwfeswffkk) = lzlreuuuie lhcwbhmxaz (gdzujdyavv, 79 - 86)	Positive	17 Oct 2024
				Nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD)	lssvswztwo(bvopzlogxk) = fabvyagtkk puruipfmjp (mcnoygfgrp ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis